. 2015 Aug 18;173(5):541–551. doi: 10.1530/EJE-15-0554
This work is licensed under a Table 5.
Baseline-adjusted PD parameters of IGFBP3.
| Dose | AUEC0–t (mg·h/l) Mean (s.d.) | AUEC0–168 (mg·h/l) Mean (s.d.) | Emax (m/l) Mean (s.d.) | TEmax (h) Median (range) |
|---|---|---|---|---|
| 3 mg (n=6) | 26.6 (116.9) | 37.8 (47.0) | 0.8 (0.3) | 48.0 (24.0–72.0) |
| 10 mg (n=6) | 136.8 (140.3) | 105.8 (42.6) a | 1.6 (42.6) | 72.0 (48.0–72.0) |
| 25 mg (n=6) | 81.8 (109.0) | 104.2 (65.5) | 1.5 (0.7) | 60.0 (48.0–72.0) |
| 35 mg (n=6) | 202.5 (60.7) | 168.7 (36.1) a | 1.9 (0.2) | 72.0 (72.0–72.0) |
| 50 mg (n=6) | 157.6 (161.2) | 119.8 (91.1) | 1.5 (0.7) | 72.0 (48.0–120.0) |
| 70 mg (n=6) | 389.8 (255.8) | 234.4 (120.0) | 2.3 (1.0) | 84.1 (72.0–168.0) |
| 100 mg (n=6) | 310.4 (149.5) | 209.6 (92.5) | 2.0 (0.7) | 96.0 (72.0–120.0) |
| Pooled placebo (n=14) | 24.4 (191.1) | 29.2 (92.8) | 0.8 (0.7) | 72.0 (24.0–336.0) |
a
n=5.